Compare · BOOM vs EW
BOOM vs EW
Side-by-side comparison of DMC Global Inc. (BOOM) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- BOOM operates in Industrials, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $50.78B, about 471.8x BOOM ($107.6M).
- EW has been more active in the news (5 items in the past 4 weeks vs 1 for BOOM).
- EW has more recent analyst coverage (25 ratings vs 6 for BOOM).
- Company
- DMC Global Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $107.6M
- $50.78B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 6
- 25
DMC Global Inc.
DMC Global Inc. provides a suite of technical products for the energy, industrial, and infrastructure markets worldwide. The company operates in two segments, NobelClad and DynaEnergetics. Its NobelClad segment produces and sells explosion-welded clad metal plates for use in the construction of heavy, corrosion resistant pressure vessels, and heat exchangers for oil and gas, chemical and petrochemical, alternative energy, hydrometallurgy, aluminum production, shipbuilding, power generation, and industrial refrigeration industries. The company sells its products through direct sales personnel, program managers, and independent sales representatives. Its DynaEnergetics segment designs, manufactures, markets, and sells perforating systems, including initiation systems, shaped charges, detonating cords, gun hardware, and control panels; and associated hardware for the oil and gas industry. It sells its products through direct selling, distributors, and independent sales representatives. The company was formerly known as Dynamic Materials Corporation and changed its name to DMC Global Inc. in November 2016. DMC Global Inc. was founded in 1965 and is headquartered in Broomfield, Colorado.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest BOOM
- DMC Global to Report Third Quarter Financial Results on October 27, 2026
- SEC Form 10-Q filed by DMC Global Inc.
- DMC Global Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- DMC Global Reports Second Quarter Financial Results
- DMC Global Schedules Second Quarter Earnings Release and Conference Call
- Exec. Chair, President & CEO Oleary James converted options into 72,040 shares and returned $450,970 worth of shares to the company (72,040 units at $6.26) (SEC Form 4)
- NobelClad Expands Capabilities in the Americas with Weld Overlay Services
- SEC Form SD filed by DMC Global Inc.
- Chief Accounting Officer Seger Brett A. covered exercise/tax liability with 230 shares, decreasing direct ownership by 1% to 21,408 units (SEC Form 4) (tax withholding)
- Director Kelly Michael Aaron was granted 16,937 shares, increasing direct ownership by 35% to 65,590 units (SEC Form 4)
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision